Receive our newsletter – data, insights and analysis delivered to you
SOM Biotech|10 February 2020

Programme SOM0044 for Parkinson’s Disease

SOM0044 is a small molecule for the treatment of Parkinson’s disease.

SOM0044 is a small molecule for the treatment of Parkinson’s disease.

Parkinson’s disease is a slowly progressive neurodegenerative disorder characterised by bradykinesia, rigidity, tremor at rest, shuffling gait and postural instability. The disease is caused by ageing, genetic and environmental factors. Symptoms usually appear around 60 years of age. Affects an estimated 10 million people worldwide. Available treatments are symptomatic, mainly involving dopaminergic agents for the control of motor function.

Unique advantages of SOMAI PRO include identification of new mechanisms of action of drugs (biological activity defined by Molecular Field Maps, which were not described...
The current Covid-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy